Abstract
Among survivors of ventricular fibrillation or sustained ventricular tachycardia causing severe symptoms, the implantable cardioverter-defibrillator is superior to antiarrhythmic drugs for increasing overall survival.
Keywords
Affiliated Institutions
Related Publications
Canadian Implantable Defibrillator Study (CIDS)
Background —Patients surviving ventricular fibrillation (VF) or sustained ventricular tachycardia (VT) are at a high risk of death due to a recurrence of arrhythmia. The implant...
Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular Arrhythmia
In patients with a prior myocardial infarction who are at high risk for ventricular tachyarrhythmia, prophylactic therapy with an implanted defibrillator leads to improved survi...
Initial Clinical Experience with a New Small Sized Third‐Generation Implantable Cardioverter Defibrillator: Results of a Multicenter Study
This study reports the acute clinical experience with the new CPI VENTAK MINI: a small sized (68 cc), implantable cardioverter defibrillator (ICD) with 33 J stored energy. Impla...
Amiodarone in Patients with Congestive Heart Failure and Asymptomatic Ventricular Arrhythmia
Although amiodarone was effective in suppressing ventricular arrhythmias and improving ventricular function, it did not reduce the incidence of sudden death or prolong survival ...
Publication Info
- Year
- 1997
- Type
- article
- Volume
- 337
- Issue
- 22
- Pages
- 1576-1584
- Citations
- 3203
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.1056/nejm199711273372202